Related Experiment Video

Updated: May 30, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

[Urticaria pigmentosa: two different clinical presentations in pediatric patients]

Julieta Spada1, Mariana Lequio, María de los Ángeles Pyke

  • 1Centro de Investigaciones Dermatológicas, Buenos Aires, Argentina. julieta@spada.com.ar

Archivos Argentinos De Pediatria
|August 11, 2011
PubMed

Insights

Urticaria pigmentosa (UP), a skin condition, presents in early childhood or adulthood. Recognizing both typical and unusual presentations is key for pediatricians managing this mast cell disorder.

Area of Science:

  • Dermatology
  • Pediatrics
  • Pathology

Background:

  • Urticaria pigmentosa (UP) is the most common manifestation of cutaneous mastocytosis.
  • UP exhibits a bimodal incidence, with peaks in early childhood and adulthood.
  • Darier's sign is a characteristic clinical finding in affected skin.

Observation:

  • Early-onset UP generally has a favorable prognosis, often resolving by adolescence.
  • Late-onset UP is frequently linked to persistent disease or systemic involvement.
  • This report details two UP cases: one classic and one with an atypical presentation.

Findings:

  • The study highlights the diverse clinical spectrum of urticaria pigmentosa.
  • It emphasizes the importance of considering both typical and unusual UP presentations in pediatric cases.
  • The findings suggest a unified approach to managing UP, regardless of onset age or presentation.

Implications:

  • Pediatricians should be aware of the varied clinical presentations of urticaria pigmentosa.
  • Early recognition and diagnosis of UP can lead to timely management and improved outcomes.
  • Understanding the prognostic differences between early and late-onset UP is crucial for patient care.

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Related Concept Videos

Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...